tapebrief
Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

GEHC · Q2 2025 Earnings

GE HealthCare

Reported July 30, 2025

30-second summary

30-second take. GE HealthCare put up Q2 FY2025 revenue of $5.01B (+3% YoY, +2% organic) and non-GAAP EPS of $1.06, but the story is the FY guide — adjusted EPS raised to $4.43-$4.63 from $3.90-$4.10, FCF lifted to "at least $1.4B" from "at least $1.2B", and EBIT margin guidance moved up roughly 100bps. Of the ~53 cents midpoint raise, ~40 cents is tariff mitigation and ~13 cents is commercial execution, tax, and interest — not a step-change in underlying demand: organic growth was raised only to ~3% from 2-3%, and Q3 FY2025 organic growth is guided to the same 2-3% with EPS down high-single-digits YoY. Backlog of $21.3B and a 1.07x book-to-bill set up an H2 weighted to product launches management is positioning as the strongest in years.

Headline numbers

EPS

Q2 FY2025

$1.06

Revenue

Q2 FY2025

$5.01B

+3.0% YoY

Gross margin

Q2 FY2025

39.6%

Free cash flow

Q2 FY2025

$0.01B

Operating margin

Q2 FY2025

13.1%

Key financials

Q2 FY2025
MetricQ2 FY2025YoY
Revenue$5.01B+3.0%
EPS$1.06—
Gross margin39.6%—
Operating margin13.1%—
Free cash flow$0.01B—

Guidance

Prior quarter data unavailable — comparison not possible.

Segment KPIs

Q2 FY2025
SegmentQ2 FY2025YoY
Imaging$2.204B+2.0%
Advanced Visualization Solutions$1.289B+3.0%
Patient Care Solutions$0.778B+1.0%
Pharmaceutical Diagnostics$0.729B+14.0%

Other KPIs

Q2 FY2025
SegmentQ2 FY2025
Organic Revenue Growth2%
Book-to-Bill Ratio1.07x
Organic Orders Growth3%
Adjusted EBIT Margin14.6%
Net Income Margin9.7%
Imaging Segment EBIT Margin8.5%
Advanced Visualization Solutions EBIT Margin20.7%
Pharmaceutical Diagnostics EBIT Margin29.3%

Management tone

Management's posture is meaningfully more prescriptive and forward-leaning than the typical GE HealthCare commentary. The hedging that has historically wrapped China and macro language is still present, but it sits underneath a clear thesis: tariff mitigation is converting from a cost story into a structural supply-chain win, and the H2/2026 product cycle is being positioned as a major step-up in competitive capability.

The tariff narrative is the cleanest shift. In April, guidance baked in 85 cents of net tariff EPS impact and was framed as a major headwind. This quarter, that figure is 45 cents, and management characterizes the supply chain changes as "no regrets" — i.e. structural even if tariffs ease further. The quote: "With the easing of tariffs, we expect to realize an improvement of approximately 40 cents from the prior full-year adjusted EPS guidance...The total net tariff impact in our adjusted EPS guidance for 2025 is now 45 cents." This is what's driving most of the EPS raise, with an additional ~13 cents from commercial execution, tax, and interest.

The product-cycle language stepped up. Management paraphrased the H2/2026 launch cadence as positioning GEHC to close portfolio gaps versus competitors across MR, CT, and molecular imaging, with new product introductions already generating over 50% of sales. The framing pairs acknowledgment of past portfolio gaps with confidence in the upcoming cadence — a tone shift that matters for how investors price the 2026 setup.

China is the one area where the tone moved the other direction. The H1 outperformance is acknowledged, but H2 is being modeled cautiously, with management describing a "cautious view" on tender progress and stating the full-year ~3% organic guide is not counting on any meaningful step up in China. This is either conservative setup or honest read of tender timing — likely both.

Gross margin commentary reframes pressure as a positive signal. Management attributed ~50bps of gross margin impact to programs shifting from pre-technical to technical feasibility (i.e. R&D progressing closer to launch, moving spend from R&D into cost of goods sold) and another ~50bps to taking on enterprise multi-vendor service contracts where margins start low and improve as accounts convert to GEHC equipment. This is the kind of framing that only works if the underlying business is actually accelerating; it would read as excuse-making otherwise.

Recurring themes management leaned on this quarter:

Nuclear medicine as high-growth therapy enabler (double-digit orders; Flocardo/PSMA/amyloid/cardiac PET momentum)D3 strategy convergence (devices + drugs + digital/AI) driving enterprise deal winsInnovation pipeline filling decade-old competitive gaps (photon counting CT, full-body PET, ultrasound refresh, vascular/neuro)Tariff mitigation as no-regret supply chain optimization creating structural advantagesRecord backlog ($21.3B) and book-to-bill (1.07x) enabling H2 acceleration and 2026 confidenceEnterprise multi-year service contract mix shift improving recurring revenue and margin trajectories

Risks management surfaced:

China tender cycle extension and delayed bid-to-award timelines (modeling 'slightly more conservative back half')Tariff volatility and broader trade policy uncertainty despite recent 'clarity' (still only modeling announced/agreed tariffs)PDX gross margin pressures from startup costs of new radiopharmaceutical manufacturing footprint (18 of 25 CMOs on track)Patient care solutions segment EBIT margin deterioration (down 240 bps YoY) from unfavorable mix and inflationPhoton counting CT competitive landscape requiring execution risk on regulatory approval and commercial differentiation vs. existing entrant

What to watch into next quarter

Whether Q3 organic growth lands above the 2-3% guide. Management telegraphed conservatism on China for H2; a beat here would validate that the FY ~3% raise was prudently set rather than stretched.

Pharmaceutical Diagnostics organic growth trajectory as the 7 remaining CMOs (of 25) come online and as the NMP acquisition contribution starts to anniversary. Organic was only +5% this quarter against a tough comp; the reported +14% will compress as the acquisition rolls into the base.

Imaging EBIT margin recovery from 8.5%. The H2 product launches (photon counting CT in particular) are the test of whether the portfolio-gap-closing framing converts to segment economics.

Patient Care Solutions margin stabilization. Down 240bps YoY this quarter with no recovery timeline disclosed; another step down would force a harder question on portfolio role.

2026 tariff exposure disclosure. Management said 2026 net tariff impact will be "less than 45 cents" — the actual figure, when it comes, will determine how much of the 2025 EPS raise is durable versus a 2026 give-back.

Flyrcado customer onboarding time moving from 90 days toward the 30-day goal. This is the gating factor on near-term nuclear medicine revenue velocity.

Sources

  1. GE HealthCare Q2 2025 earnings press release, filed with SEC: https://www.sec.gov/Archives/edgar/data/1932393/000193239325000048/release2q25earnings.htm

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.